explore -WSS

explore

author：explore 2025-09-29 18:16:09 - browse：7

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

WSS

Letters to First Opinion on caregivers, digital health, and more

Intellia reports positive results for its CRISPR

NIH documents show early flaws of $1.6 billion long Covid program

NIH documents show early flaws of $1.6 billion long Covid program

FDA's Pazdur wants cancer trials to range beyond China alone

CRISPR pioneers react to Casgevy, first gene

focus

explore

hotspot

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Tori Bowie and the unacceptable rates of Black maternal death

Wegovy, Zepbound and weight loss drugs that preserve muscle

Psychedelics group wrestles with new pharma identity

PBM reforms clear House panel

Guidelines to prevent youth baseball injuries need more muscle

HIV drugs protect against transmission, even in unprotected sex

Affirmative action in medical school literally saved lives

Ransomware attacks on hospitals: Study outlines patient impact

hotspot

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

CRISPR pioneers react to Casgevy, first gene

CRISPR pioneers react to Casgevy, first gene

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

See how much Covid

Wikipedia

focus

focus

Wikipedia